Leicester

Horizontal Tabs

Overview
Our Centre 

Cancer patients in Leicester have access to early phase oncology and haematology clinical trials through the Hope Cancer Trials Centre which is a dedicated cancer specific clinical area. It is the only such unit in the Midlands and attracts referrals from far afield.  The Centre’s partnership with the Leicester NIHR Clinical Research Facility has generated and sustained a critical mass of infrastructure providing the capability to perform all phases of studies including first in human.  Leicester has an exceptional track record exemplified by the number of companies that use us as preferred partners and over the last 5-years we have worked with 64 companies in 46 disease areas.  Leicester is one of the most ethnically diverse areas in England and Wales and studies are ongoing to explore clinical trial engagement among underserved groups, including ethnic minorities, to ensure equity of access for all cancer patients.

 
Unique Selling Points
 

Detection of cancer and recurrence through circulating tumour DNA (ctDNA)

In Leicester, Professor Jacqui Shaw’s lab is internationally recognised as leaders in this field.  The group has demonstrated a patient-specific ctDNA method to detect preclinical metastasis up to 3-years ahead of clinical relapse that allows for longitudinal monitoring of patients with breast cancer regardless of molecular sub-type.

 

Therapeutic Prevention

 

Leicester is one of the leading cancer centres in the world renowned for work in cancer prevention with focus on the discovery, preclinical development and clinical evaluation of therapies for the prevention of cancer.  This includes investigating repurposed drugs and natural compounds such as resveratrol and curcumin.  Building on our long track-record of developing therapies for cancer prevention, our main activity over the next quinquennium will centre on our CRUK-funded COLO-PREVENT platform for evaluating the efficacy of colorectal cancer preventive therapies

Personalising mesothelioma treatment

Leicester is the UK’s leading national referral centre for systemic therapy and has consistently played a leading role in national and global randomised trials.  Translational research in mesothelioma is concerned with deciphering molecular and cellular determinants of therapeutic response. In the CRUK CONFIRM phase 3 trial, we were the first to show that immunotherapy (nivolumab) confers a significant clinical benefit for patients with mesothelioma, resulting in a change in clinical practice. The now completed, Leicester-led, MiST trial was the world’s first personalised therapy umbrella trial which aims to accelerate the identification of effective stratified therapy for mesothelioma.

Preclinical models enabling drug and biomarker discovery

Professor Catrin Pritchard’s lab has pioneered an innovative patient-derived explant platform that contextually conserves human tumour architecture for drug discovery and biomarker validation.  The Explant Facility is run by Dr Gareth Miles and has numerous industry collaborators.

Personalised treatment in B cell malignancies

 Leicester has led on global first in man/early phase clinical trials.  One of our main areas of clinical expertise is in delivering trials testing bispecific antibodies. Translational work in Professor Martin Dyer’s and Dr Harriet Walter’s group focusses on the study of intrinsic and extrinsic mechanisms of resistance and exceptional responders, along with dynamic risk prediction using cfDNA/ctDNA, all aligned to our extensive early phase portfolio.

 

Our patient population
University Hospitals of Leicester NHS Trust is one of the busiest Cancer Centres in the UK; Q2 2018-2019 8680 patients were diagnosed.  Through the South East Midlands Oncology Centre, UHL serves a population of 3 million.  
 
Organisations affliated with the Leicester ECMC:
 
Our location
We are located in the East Midlands conveniently situated for road and rails links being 4 miles from the M1/M69 junction and 10 minutes on foot from Leicester train station.  For international travel, Leicester ECMC is 22 miles from East Midlands Airport 
 
Contact the Centre Manager:
Stephanie Moutrey

 

Address 
Leicester Cancer Research Centre
Clinical Sciences Building
University of Leicester
Leicester Royal Infirmary
Leicester, LE2 7LX

 

Team Members
Centre Co-Lead
+44 (0) 116 258 7603

Harriet is Associate Professor of Medical Oncology and Director of the Hope Cancer Trials Centre.  As a medical oncologist, Harriet specialises in Phase I trials and leads the Phase I programme.  She is the current joint lead for the Leicester ECMC and leads a team of over 40 clinical staff membrs to deliver the cancer clinical research portfolio at University Hospitals of Leicester and University of Leicester.  Harriet runs a translational research programme within The Ernest and Helen Scott Haematological Research Institute, aligned to the early phase portfolio, with a particular focus on rare lymphoid malignancies.  Harriet also works in drug development and is a medical advisor in CRUK’s Centre for Drug Development.

More
Centre Co-Lead
+44 (0) 116 223 1851
Karen, Director of Leicester Cancer Research Centre and leads the Cancer Prevention Group at the Leicester ECMC which focusses on the discovery and development of agents for the prevention of cancer, optimising the translation of these therapies to the clinic and supporting their wider implementation in appropriate high-risk populations. She has an interest in both natural compounds such as curcumin and resveratrol, and existing drugs that can be repurposed for cancer prevention. Intrinsic to her work is the discovery and development of pharmacodynamic biomarkers for monitoring activity in humans, identifying surrogate endpoints, and the use of clinically relevant models, informed by reverse translation of trials results. Karen is also co-Chair of the UK Therapeutic Cancer Prevention Network and represents this Network on the steering group of the Cancer Prevention Europe Consortium.
 
More
Patient and Public Involvement and Engagement (PPIE) Lead

Liz is the Cancer Portfolio and Recruitment Lead for the Hope Cancer Trials Centre. 

Patients and the public are at the heart of our research and it is vital that their voices are heard to shape this and bring a new perspective. 

An important aim of our team is to take an inclusive approach and tackle health inequities through meaningful PPIE. Being based in such a diverse community as Leicester is a privilege and provides a fantastic opportunity to achieve this.  

To ensure we are reflecting the needs of our diverse community within our PPIE, Liz and the team would like to hear from all members of our community with lived experience and/or who have an interest in cancer research. 

 

More

Scientific & Operational Team

Professor of Cancer Imaging and Radiology
Professor of Haemato-Oncology
+44 (0) 795 085 9586
Professor of Translational Cancer Genetics
+44 (0) 116 252 3148
Chair of Thoracic Medical Oncology
+44 (0) 116 223 1854
Professor of Radiotherapy Genetics
+44 (0)116 252 3433

Operational Team

R&D Contact
+44 (0) 116 258 4109
Lead Research Nurse
+44 (0) 116 258 5773
Research Nurse
0116 204 7872
Early Trials Pharmacist
Biobank Contact
+44 (0) 116 252 3228
Adult Expertise
Treatment Modalities 
Immunotherapy
Small Molecules
Facilities/Translational Research 
  • Dedicated 24 hour stay facilities (including weekends)
  • On-site pharmacy
  • Biobanking facilities
  • Dedicated research staff
  • Snap freezing facilities
  • On-site ITU (intensive treatment unit)
  • On-site central lab
  • Specific Phase 1 Facility 
 
Cancer Types

We have expertise in both solid tumours and haematological malignancies. Translation of research expertise into clinical use is achieved via our Leicester Molecular Diagnostics facility working in collaboration with our local ISO 15189 (Medical Laboratories) accredited NHS genetic laboratory (Ref 8069) to bring research testing in line with this standard.

Specific tumour type expertise in colorectal cancer, breast cancer, B cell lymphoma and malignant pleural mesothelioma

Expertise and Drug/Treatment Modalities

We have expertise in the following:

  • Cancer Prevention
  • Preclinical models of cancer: explants and PDX models.
  • Genomic testing (tissue and circulating tumour DNA), cfDNA and MRD analysis
  • Late effects of radiotherapy
  • Combination therapies
  • Bispecific Antibodies
Radiotherapy

We have regular access to photon radiotherapy and we have research expertise in the following:

Intensity Modulated Radiotherapy (IMRT)

Image Guided Radiotherapy (IGRT)

Stereotactic Radiotherapy (SBRT/SABRT)

Internal Radiotherapy

Radiosurgery

Brachytherapy

We also use DISH to assist with breathing patterns.

 

Case Study
Case Studies 
NP39488
Roche NP39488 Bispecific trial with CD20/CD3 antibody. One of 3 centres in the UK to be part of this Phase I trial. Requires inpatient stay for the first 2 cycles and nursing staff are supported by ECMC funding. Provides an alternative option to CAR-T and also for patients who have relapsed post CAR-T cell therapy. We are also conducting translational and reverse translation studies in parallel to understand mechanisms of resistance and response according to CD20 expression using single cell technologies.  
DIRECT Study
We are involved in the design and conduct of a multi-ECMC centre study (DIRECT) looking at the utility of ctDNA in front line DLBCL as a tool to predict poor prognosis at diagnosis and follow minimal residual disease. This study involves Cambridge and London sites and will start to recruit Q2.
DLBCL
We are developing single cell sequencing in DLBCL using 10x technology and CyTOF to study immune profiling as a marker to response to immunotherapies (partly funded by ECMC Leicester).
Leicester has expertise in the development and characterisation of drug resistant models to identify molecular biomarkers for treatment stratification